Orris

Zoonotic lung disease for md exams 10 marks answer from fishman and murray only with dosage

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have very rich data from both textbooks. I have enough content to write a comprehensive 10-mark MD exam answer. Let me compile everything now.

Zoonotic Lung Diseases

A 10-Mark MD Examination Answer Sources: Fishman's Pulmonary Diseases and Disorders, 5th Ed. | Murray & Nadel's Textbook of Respiratory Medicine

Definition & Introduction

Zoonotic pneumonias are caused by pathogens transmitted from animals (vertebrates or arthropod vectors) to humans, producing primary pulmonary disease or pulmonary involvement as part of a systemic illness. Routes of acquisition include inhalation of aerosols, direct animal contact, arthropod bites, and ingestion. Clinical presentations overlap, and a thorough epidemiologic (animal exposure) history is essential to diagnosis.
(Fishman's, p. 2452)

Classification (Fishman's Table 138-1)

CategoryOrganismDisease
Live animal/arthropod contactChlamydia psittaciPsittacosis
Francisella tularensisTularemia
Pasteurella multocidaPasteurellosis
Yersinia pestisPlague
Rhodococcus equiRhodococcus pneumonia
Soil/inert animal productsBacillus anthracisInhalation anthrax
Brucella spp.Brucellosis
Burkholderia pseudomalleiMelioidosis
Coxiella burnetiiQ fever

1. Psittacosis (Chlamydia psittaci)

Epidemiology: Accounts for <1% of community-acquired pneumonia (CAP). >70% of cases have clear bird exposure - psittacine birds (parakeets, cockatiels, parrots), canaries, chickens, turkeys, pigeons. Transmission is via inhalation of aerosols from contaminated bird excreta, respiratory secretions, or bedding. Age group most affected: 40-65 years.
Pathogenesis: Obligate intracellular bacterium. Uses a Type III secretion system; inhibits lysosomal fusion; inhibits apoptosis; Th1 responses are important for control.
Clinical Features: Incubation 5-14 days. High fever, chills, severe headache, myalgia (especially head and neck), and a dry nonproductive cough. Pulse-temperature dissociation (relative bradycardia despite high fever) is a characteristic finding. Splenomegaly and a pale macular rash (Horder spots) may be seen. Complications: myocarditis, pericarditis, endocarditis, hepatitis, encephalitis.
Radiology: Lobar consolidation or interstitial changes. (Murray & Nadel, p. 1013)
Diagnosis: PCR on respiratory samples or blood (now preferred). Microimmunofluorescence (more sensitive than complement fixation). A 4-fold rise in IgG is diagnostic; CF test cross-reacts with C. burnetii and Brucella.
Treatment:
  • Doxycycline is first-line. Treat for a minimum of 2 weeks after fever resolves (due to relapse risk).
  • Macrolides (azithromycin, clarithromycin) are an alternative, especially in pregnancy.
  • (Murray & Nadel, p. 1013; Fishman's, p. 2459)

2. Q Fever (Coxiella burnetii)

Epidemiology: Worldwide distribution. Reservoir: cattle, sheep, goats. Transmission via inhalation of contaminated birthing products, placentae, milk, wool, or windblown dust from contaminated soil. Slaughterhouse workers, farmers, and veterinarians are at risk. A single organism can cause disease.
Clinical Features:
  • Acute Q fever: Self-limiting febrile illness; pneumonia in ~50% - may be asymptomatic or mild. Atypical pneumonia pattern with fever, headache, and nonproductive cough. Hepatitis is common. Round/oval consolidation ("round pneumonia") on chest X-ray is characteristic.
  • Chronic Q fever: Endocarditis (most serious manifestation, especially on abnormal valves), hepatitis, osteomyelitis. Can occur months to years after initial infection.
Diagnosis: Serology (indirect immunofluorescence is gold standard). Phase I and Phase II antibodies: Phase II IgG > Phase I IgG in acute disease; in chronic disease, Phase I IgG titer ≥1:800 is highly suggestive of endocarditis. PCR is available.
Treatment:
  • Acute Q fever: Doxycycline 100 mg twice daily for 14 days
  • Q fever in pregnancy: TMP-SMX for entire pregnancy (to prevent stillbirth)
  • Chronic Q fever/Endocarditis: Doxycycline 100 mg twice daily + hydroxychloroquine 200 mg three times daily for ≥18 months (for native valve); at least 24 months (for prosthetic valve)
  • (Murray & Nadel, p. 1010-1011; Fishman's)

3. Tularemia (Francisella tularensis)

Epidemiology: Endemic in North America, Europe, and Asia. Reservoir: rabbits, hares, squirrels, muskrats. Transmission via handling infected animals (hunters, trappers), tick/deer-fly bites, lawn mowing/gardening (disturbed soil), inhalation of aerosols, or ingestion. As few as 10-50 organisms can initiate disease by inhalation. Category A bioterrorism agent.
Pulmonary Disease: Primary pneumonia follows inhalation. Inflammation, necrosis, granuloma formation, hilar/mediastinal adenopathy, pleural effusion. Pneumonia may also complicate ulceroglandular (25-50%) or typhoidal forms.
Clinical Features: Nonproductive cough, fever, severe headache, myalgia, shaking chills. In typhoidal tularemia - constitutional symptoms without a local lesion. Pleural effusions may be serosanguineous or bloody - an important distinguishing feature (uncommon in other pneumonias except anthrax).
Radiology: Bronchopneumonia, hilar adenopathy, mediastinal widening, unilateral or bilateral pleural effusions (Fishman's Fig. 138-2).
Diagnosis: Serology is the method of choice. Single convalescent titer ≥1:160 highly suspect; 4-fold rise between acute and convalescent samples is more reliable. PCR available. Culture is hazardous (BSL-3). (Fishman's, p. 2455; Murray & Nadel, p. 1018)
Treatment:
  • Streptomycin 1 g IM twice daily for 10 days - drug of choice (most reliably bactericidal)
  • Gentamicin 5 mg/kg/day IV divided every 8 h for 10 days - acceptable alternative
  • Doxycycline 100 mg twice daily for 14-21 days - oral option; higher relapse rate than aminoglycosides
  • Ciprofloxacin 400 mg IV/500 mg orally twice daily for 10 days - alternative, especially in mass casualty/bioterrorism
  • (Murray & Nadel, p. 1019; Fishman's, p. 2455)

4. Plague Pneumonia (Yersinia pestis)

Epidemiology: Worldwide including Asia, southwest USA (New Mexico, Arizona, Colorado). Reservoir: ground squirrels, prairie dogs, rats, rabbits. Rodent fleas transmit between hosts. Humans infected by flea bite, handling infected carcasses, or inhaling aerosol from pneumonic patient/animal. Category A bioterrorism agent (potential for aerosol release with secondary person-to-person transmission).
Clinical Forms:
  1. Bubonic (most common in USA) - flea bite, painful lymphadenopathy (bubo), fever
  2. Septicemic - septic shock, DIC
  3. Pneumonic - primary (inhalation, incubation 1-3 days) or secondary to bubonic/septicemic
Pneumonic Plague Clinical Features: Rapid onset - flu-like illness progressing within hours to high fever, chest pain, productive cough, dyspnea, hemoptysis, shock. WBC markedly elevated. DIC common. Untreated, case fatality ~100%.
Radiology: Bilateral lower lobe alveolar opacities; may show cavitation, nodules, pleural effusion. (Murray & Nadel, p. 1016)
Diagnosis: Blood culture, sputum/BAL culture, bubo aspirate. Direct Gram or Wayson stain shows bipolar "safety pin" pattern. Immunofluorescence. PCR. Serology (passive hemagglutination, titer ≥1:128).
Treatment: (Must be started within 24 hours of symptom onset for pneumonic plague)
  • Streptomycin 1 g IM twice daily for 10 days - gold standard
  • Gentamicin 5 mg/kg/day IV for 10 days - preferred in modern practice
  • Doxycycline 100 mg twice daily for 10-14 days - acceptable alternative; also used for post-exposure prophylaxis
  • Ciprofloxacin 400 mg IV or 500 mg orally twice daily for 10-14 days
  • Chloramphenicol - used for plague meningitis; 25 mg/kg IV 4 times daily
  • Post-exposure prophylaxis: Doxycycline 100 mg twice daily for 7 days OR ciprofloxacin 500 mg twice daily for 7 days
  • (Murray & Nadel, p. 1017; Fishman's, p. 2456)

5. Inhalation Anthrax (Bacillus anthracis)

Epidemiology: Worldwide in warmer regions with grazing animals. Industrial ("woolsorter's disease") - exposure to animal hides, wool, hair, bone meal. Also in those using or handling animal products as a hobby. Category A bioterrorism agent (2001 US bioterror attacks via postal letters). Spores are resistant; can remain viable for decades in soil.
Pathogenesis: Inhalation of spores (>8 µm for upper respiratory tract; 1-5 µm for alveolar deposition). Spores phagocytosed by alveolar macrophages - transported to mediastinal and peribronchial lymph nodes - germinate - produce toxins (lethal toxin + edema toxin) - massive hemorrhagic mediastinitis.
Clinical Features:
  • Stage 1 (prodromal, 1-5 days): Mild fever, malaise, myalgia, nonproductive cough - mimics influenza
  • Stage 2 (fulminant): Abrupt onset of high fever, severe dyspnea, stridor, cyanosis, diaphoresis, shock. Meningitis in ~50%. Mediastinal widening is characteristic.
  • No true lobar pneumonia - the pathology is hemorrhagic mediastinitis and toxemia.
Radiology: Widened mediastinum (most characteristic), pleural effusions (often bloody - a key distinguishing sign, also seen in tularemia). Infiltrates present in some cases. No cavitation.
Diagnosis: Blood cultures (positive in >90% if untreated). PCR of blood/respiratory samples. Serology. Gram stain of blood - large Gram-positive rods in chains.
Treatment:
  • Ciprofloxacin 400 mg IV every 12 hours (first-line for bioterrorism strains due to possible penicillin resistance)
  • Doxycycline 100 mg IV every 12 hours - alternative
  • Combination therapy recommended for inhalation anthrax: Add one or two additional bactericidal agents:
    • Plus penicillin G, ampicillin, clindamycin, rifampin, vancomycin, or linezolid
  • Continue IV x 60 days total (for natural disease 7-10 days; for bioterrorism 60 days due to spore persistence)
  • Anthrax antitoxin (raxibacumab or obiltoxaximab) may be added for severe inhalation anthrax
  • Post-exposure prophylaxis: Ciprofloxacin 500 mg orally twice daily or doxycycline 100 mg twice daily for 60 days + anthrax vaccine (3 doses)
  • (Murray & Nadel, p. 1014-1015; Fishman's)

6. Brucellosis (Brucella spp.)

Epidemiology: Brucella melitensis (goats, sheep - most virulent), B. abortus (cattle), B. suis (pigs), B. canis (dogs). Slaughterhouse workers, veterinarians, farmers. Transmission via ingestion of unpasteurized dairy products, contact with infected animal products, or inhalation in abattoir settings.
Pulmonary Involvement (~16%): Bronchopneumonia, nodules, hilar/paratracheal adenopathy, pleural effusion. Pulmonary manifestations are less prominent than systemic features.
Clinical Features: Undulant fever (characteristic), malaise, sweating, myalgia, arthralgia, hepatosplenomegaly.
Diagnosis: Blood culture (gold standard but slow). Serology (standard tube agglutination - titer ≥1:160 significant; 4-fold rise diagnostic). Brucella-coombs test for chronic disease. PCR.
Treatment:
  • Doxycycline 100 mg twice daily for 6 weeks + rifampin 600-900 mg/day for 6 weeks (WHO standard regimen)
  • OR Doxycycline 100 mg twice daily for 6 weeks + streptomycin 1 g IM daily for 2-3 weeks (lower relapse rate, preferred by many)
  • For neurobrucellosis: add TMP-SMX or ceftriaxone to above regimen
  • For endocarditis: triple therapy (doxycycline + rifampin + TMP-SMX or aminoglycoside) for ≥6 months
  • (Fishman's, p. 2460)

7. Pasteurella Pneumonia (Pasteurella multocida)

Epidemiology: Common commensal of oral cavity of cats (90%) and dogs (50-60%). Pulmonary infection typically in elderly patients with structural lung disease (emphysema, bronchiectasis, malignancy). Immunocompromised patients (AIDS, TNF inhibitor use) at risk. Transmission via animal bites/scratches or inhalation.
Clinical Features: Fever, productive cough, dyspnea; indistinguishable from other CAP. Empyema is more frequent than other CAP etiologies. Lobar consolidation on CXR. (Murray & Nadel)
Treatment:
  • Penicillin G 4-12 million units/day IV for 10-14 days (drug of choice)
  • If β-lactamase producing strain: Amoxicillin-clavulanate or other β-lactam/β-lactamase inhibitor combination
  • Alternatives: 2nd/3rd generation cephalosporins, tetracyclines, TMP-SMX, fluoroquinolones, chloramphenicol
  • Resistant to clindamycin and macrolides
  • (Murray & Nadel, p. 1015)

8. Melioidosis (Burkholderia pseudomallei)

Epidemiology: Endemic between latitudes 20°N and 20°S - particularly rural Southeast Asia (Thailand, Vietnam) and northern Australia. Transmission via direct contact with or penetrating wounds exposed to contaminated soil or water; inhalation possible. Diabetes mellitus is the most important risk factor (50% of cases).
Clinical Features: Wide spectrum - from subclinical seroconversion to severe pneumonia and septicemia. Pulmonary disease most common form (50% of cases) - may present as localized pneumonia or cavitary disease mimicking TB, or fulminant pneumonia with septicemia.
Radiology: Upper lobe cavitary disease (simulates TB), nodular opacities, consolidation.
Treatment:
  • Intensive phase: Ceftazidime 50 mg/kg (up to 2 g) IV every 6-8 hours for 10-14 days (preferred) OR meropenem 1 g IV every 8 hours
  • Eradication phase: TMP-SMX (160 mg TMP/800 mg SMX) twice daily for 3-6 months
  • (Fishman's, p. 2462)

Summary Table: Key Treatments at a Glance

DiseaseFirst-line DrugDoseDuration
PsittacosisDoxycycline100 mg BD≥2 weeks after fever resolves
Q fever (acute)Doxycycline100 mg BD14 days
Q fever (endocarditis)Doxycycline + hydroxychloroquine100 mg BD + 200 mg TDS≥18-24 months
TularemiaStreptomycin (or gentamicin)1 g IM BD (or 5 mg/kg/d IV)10 days
PlagueStreptomycin or gentamicin1 g IM BD (or 5 mg/kg/d IV)10 days
Anthrax (inhalation)Ciprofloxacin + combo400 mg IV Q12h60 days
BrucellosisDoxycycline + rifampin (or streptomycin)100 mg BD + 600 mg OD6 weeks (doxy)
PasteurellosisPenicillin G4-12 million units/day10-14 days
MelioidosisCeftazidime (intensive) + TMP-SMX (eradication)2 g IV Q6-8h; then TMP-SMX BD10-14 days; then 3-6 months

Bioterrorism-Relevant Zoonotic Pneumonias (Category A)

Fishman's specifically flags three agents as Category A bioterrorism pathogens with potential for aerosol weaponization:
  1. Anthrax (B. anthracis) - spore inhalation, near-100% fatal untreated
  2. Plague (Y. pestis) - pneumonic form, person-to-person transmission
  3. Tularemia (F. tularensis) - 10-50 organisms sufficient for disease
Suspect bioterrorism when: multiple simultaneous cases of unusual pneumonia, no clear epidemiologic link, or atypical geographic distribution. (Fishman's, p. 2453)
References:
  • Fishman's Pulmonary Diseases and Disorders, 5th Ed. - Chapter 138: Zoonotic and Environmental Bacterial Pneumonias, pp. 2452-2470
  • Murray & Nadel's Textbook of Respiratory Medicine - Chapter covering Psittacosis (p. 1013), Q fever (pp. 1010-1012), Plague (pp. 1016-1017), Anthrax (pp. 1014-1015), Tularemia (pp. 1018-1019), Pasteurellosis (p. 1015)
This is a shared conversation. Sign in to Orris to start your own chat.